Health TrialsbyHealthPanel

Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced NSCLC

ConditionNon-small Cell Lung Cancer
Trial statusRecruiting
Trial phaseNot listed
Trial typeObservational
Biological sexAll
Age18+
SponsorHunan Province Tumor Hospital

About this trial

This study aims to explore Survival Outcome of EGFR-TKI in Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Eligibility criteria

This trial does not accept healthy volunteers

Qualifiers

18，Advanced Non-squamous Non-small Cell Lung Cancer Confirmed by Histopathology

Uncommon EGFR Mutant Advanced NSCLC

Disqualifiers

Patients with contraindication of chemotherapy

Pregnant or breast feeding women

Trial population

Uncommon EGFR Mutant Advanced Non-small Cell Lung Cancer in China

Trial design

Design model

Cohort

Time perspective

Retrospective

Treatments tested in this trial

  • Third-generation EGFR-TKI

    Drug

    Third-generation EGFR-TKI including Osimertinib/Furmonertinib/Almonertinib, etc.

  • EGFR-TKI

    Drug

    All EGFR-TKI

Treatment groups

800 Participants
are divided into 7 treatment groups

7

Treatment groups

See each treatment group below.

Group A: Cohort 1 Uncommon EGFR exon 19del1 intervention
Group B: Cohort 2 EGFR exon 19delins1 intervention
Group C: Cohort 3 EGFR exon 18del1 intervention
Group D: Cohort 4 Common Uncommon Point Mutations1 intervention
Group E: Cohort 5 Rare Uncommon Point Mutations1 intervention
Group F: Cohort 6 Compound Mutations Uncommon With Uncommon1 intervention
Group G: Cohort 7 Compound Mutations Uncommon With Common1 intervention

Trial outcomes

Primary outcomes

1

PFS

Defined as the time from the beginning of treatment to the first imaging disease progression or death (whichever occurs first)

Time frame
5 years

Secondary outcomes

1

OS

Defined as the time from the start of treatment to the death of the subject due to any cause.

Time frame
5 years
2

ORR

Defined as the proportion of subjects achieving a complete remission (CR) or partial remission (PR) among all subjects.

Time frame
5 years

Other outcomes

Sponsors and contacts

Click on the lead sponsor to view all of their trials.

Hunan Province Tumor Hospital

Lead sponsor

Source ClinicalTrials.gov
Apply now